Technical note: Impact of dose voxel kernel (DVK) values on dosimetry estimates in
177Lu
90Y
dose-voxel-kernel
patient-specific dosimetry
radionuclide therapy
Journal
Medical physics
ISSN: 2473-4209
Titre abrégé: Med Phys
Pays: United States
ID NLM: 0425746
Informations de publication
Date de publication:
15 Sep 2023
15 Sep 2023
Historique:
revised:
23
04
2023
received:
10
12
2022
accepted:
05
08
2023
medline:
15
9
2023
pubmed:
15
9
2023
entrez:
15
9
2023
Statut:
aheadofprint
Résumé
Radiopharmaceutical therapy (RPT) is an increasingly adopted modality for treating cancer. There is evidence that the optimization of the treatment based on dosimetry can improve outcomes. However, standardization of the clinical dosimetry workflow still represents a major effort. Among the many sources of variability, the impact of using different Dose Voxel Kernels (DVKs) to generate absorbed dose (AD) maps by convolution with the time-integrated activity (TIA) distribution has not been systematically investigated. This study aims to compare DVKs and assess the differences in the ADs when convolving the same TIA map with different DVKs. DVKs of 3 × 3 × 3 mm The CoV (% maximum difference) in voxels of normalized coordinates [0,0,0], [0,1,0], and [0,1,1] were 5%(21%), 9%(35%), and 10%(46%) for the This study showed a considerable AD variability due exclusively to the use of different DVKs. A concerted effort by the scientific community would contribute to decrease these discrepancies, strengthening the consistency of AD calculation in RPT.
Sections du résumé
BACKGROUND
BACKGROUND
Radiopharmaceutical therapy (RPT) is an increasingly adopted modality for treating cancer. There is evidence that the optimization of the treatment based on dosimetry can improve outcomes. However, standardization of the clinical dosimetry workflow still represents a major effort. Among the many sources of variability, the impact of using different Dose Voxel Kernels (DVKs) to generate absorbed dose (AD) maps by convolution with the time-integrated activity (TIA) distribution has not been systematically investigated.
PURPOSE
OBJECTIVE
This study aims to compare DVKs and assess the differences in the ADs when convolving the same TIA map with different DVKs.
METHODS
METHODS
DVKs of 3 × 3 × 3 mm
RESULTS
RESULTS
The CoV (% maximum difference) in voxels of normalized coordinates [0,0,0], [0,1,0], and [0,1,1] were 5%(21%), 9%(35%), and 10%(46%) for the
CONCLUSIONS
CONCLUSIONS
This study showed a considerable AD variability due exclusively to the use of different DVKs. A concerted effort by the scientific community would contribute to decrease these discrepancies, strengthening the consistency of AD calculation in RPT.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Institute of Health, USA
ID : R01CA240706
Organisme : National Institute of Health, USA
ID : R01EB022075
Informations de copyright
© 2023 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.
Références
Sgouros G, Hobbs RF. Dosimetry for radiopharmaceutical therapy. Semin Nucl Med. 2014;44(3):172-178. doi:10.1053/j.semnuclmed.2014.03.007
Bardies M, Vergara Gil A. ABSORBED DOSE CALCULATION. International Atomic Energy Agency (IAEA). Dosimetry for Radiopharmaceutical Therapy [IAEA Preprint]; 2022:154-175. http://inis.iaea.org/search/search.aspx?orig_q=RN:53037189
Della Gala G, Bardiès M, Tipping J, Strigari L. Overview of commercial treatment planning systems for targeted radionuclide therapy. Phys Med. 2021;92:52-61. doi:10.1016/j.ejmp.2021.11.001
Auditore L, Pistone D, Amato E, Italiano A. Monte Carlo methods in nuclear medicine. In: Signore A, ed. Nuclear Medicine and Molecular Imaging. Elsevier; 2022:587-606. doi:10.1016/B978-0-12-822960-6.00136-8
Pacilio M, Lanconelli N, Lo MS, et al. Differences among Monte Carlo codes in the calculations of voxel S values for radionuclide targeted therapy and analysis of their impact on absorbed dose evaluations. Med Phys. 2009;36(5):1543-1552. doi:10.1118/1.3103401
Lanconelli N, Pacilio M, Lo MeoS, et al. A free database of radionuclide voxel S values for the dosimetry of nonuniform activity distributions. Phys Med Biol. 2012;57(2):517-533. doi:10.1088/0031-9155/57/2/517
Pistone D, Auditore L, Italiano A, Baldari S, Amato E. An analytic model to calculate Voxel S-Values for 177Lu. Biomed Phys Eng Express. 2022;8:065030. doi:10.1088/2057-1976/ac997e
Graves S, Tiwari A, Merrick M, et al. Accurate resampling of radial dose point kernels to a Cartesian matrix for voxelwise dose calculation. Published online 2020. doi:10.5281/ZENODO.3827983 (Version 1.1 at https://zenodo.org/record/7596345#.ZD1DPnbP2KJ)
Vergara Gil A. OpenDoseDVKData. Accessed 2022 https://gitlab.com/opendose/opendosedvkdata
Amato E, Minutoli F, Pacilio M, Campennì A, Baldari S. An analytical method for computing voxel S values for electrons and photons. Med Phys. 2012;39:6808-6817. doi:10.1118/1.4757912
Bolch WE, Bouchet LG, Robertson JS, et al. MIRD pamphlet no. 17: the dosimetry of nonuniform activity distributions-Radionuclide S values at the voxel level. J Nucl Med. 1999;40(1).
Dewaraja YK, Van BJ. Lu-177 DOTATATE Anonymized Patient Datasets: Multi-Time Point Lu-177 SPECT/CT Scans. Univ Michigan-Deep Blue Data. doi:10.7302/0n8e-rz46. Published online 2021.
Van BJ, Dewaraja YK. Y-90 PET/CT & SPECT/CT and corresponding contours dataset 31JULY2020. Univ Michigan-Deep Blue Data. doi:10.7302/pf4m-vn04. Published online 2020.
Uribe C, Peterson A, Van B, et al. An international study of factors affecting variability of dosimetry calculations, Part 1: design and early results of the SNMMI Dosimetry Challenge. J Nucl Med. 2021;62(3):36S-47S. doi:10.2967/jnumed.121.262748. Supplement.
Uribe C, Brosch-Lenz J, Peterson A, et al. Variability in dosimetry calculations: an analysis of the results submitted to the SNMMI Lu-177 dosimetry challenge. J Nucl Med. 2022;63(2):2351. supplement.
Dewaraja YK, Van BJ. Lu-177 DOTATATE anonymized patient datasets: lesion and organ volumes of interest. Univ Michigan-Deep Blue Data. doi:10.7302/vhrh-qg23. Published online 2021.
RAdiation Dose Assessment Resource (RADAR)-The Decay Data. Accessed 2022. http://www.doseinfo-radar.com/RADARDecay.html
National Nuclear Data Center. Accessed 2018. http://www.nndc.bnl.gov/index.jsp
NUCLEIDE. Accessed 2022. http://www.nucleide.org/DDEP_WG/DDEPdata.htm
García-Toraño E, Peyres V, Bé MM, Dulieu C, Lépy MC, Salvat F. Simulation of decay processes and radiation transport times in radioactivity measurements. Nucl Instruments Methods Phys Res Sect B Beam Interact with Mater Atoms. 2017;396:43-49. doi:10.1016/j.nimb.2017.02.002
Agency NE. PENELOPE 2018: A Code System for Monte Carlo Simulation of Electron and Photon Transport. 2019. doi:10.1787/32da5043-en
Evaluated Nuclear Structure Data File. Accessed 2022. https://www.nndc.bnl.gov/ensdf/
National Nuclear Data Center NuDat (Nuclear Structure and Decay Data). NuDat 3.
Mougeot X. Reliability of usual assumptions in the calculation of β and ν spectra. Phys Rev C. 2015;91(5):55504. doi:10.1103/PhysRevC.91.055504
Van B, Dewaraja YK, Niedbala JT, et al. Experimental validation of Monte Carlo dosimetry for therapeutic beta emitters with radiochromic film in a 3D-printed phantom. Med Phys. doi:10.1002/mp.15926. Published online 2022.
Cross WG. Variation of beta dose attenuation in different media. Phys Med Biol. 1968;13(4):611-618. doi:10.1088/0031-9155/13/4/310
Eckerman KF, Westfall RJ, Ryman JC, Cristy M. Availability of nuclear decay data in electronic form, including beta spectra not previously published. Health Phys. 1994;67(4):338-345. doi:10.1097/00004032-199410000-00004
Eckerman KF, Westfall RJ, Ryman JC, Cristy M. Nuclear Decay Data Files of the Dosimetry Research Group. United States; 1993. http://inis.iaea.org/search/search.aspx?orig_q=RN:25039816
Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2020;1253(20):1-13. doi:10.1016/S2468-1253(20)30290-9
Taprogge J, Wadsley J, Miles E, Flux GD. Recommendations for multicentre clinical trials involving dosimetry for molecular radiotherapy. Clin Oncol (R Coll Radiol). 2021;33(2):131-136. doi:10.1016/j.clon.2020.12.002
Mora-Ramirez E, Santoro L, Cassol E, et al. Comparison of commercial dosimetric software platforms in patients treated with 177Lu-DOTATATE for peptide receptor radionuclide therapy. Med Phys. 2020;47(9):4602-4615. doi:10.1002/mp.14375